Eurican P

País: Irlanda

Língua: inglês

Origem: HPRA (Health Products Regulatory Authority)

Ingredientes ativos:

Canine parvovirus

Disponível em:

Merial Animal Health Limited

Código ATC:

QI07AD01

DCI (Denominação Comum Internacional):

Canine parvovirus

Dosagem:

.

Forma farmacêutica:

Lyophilisate for suspension

Tipo de prescrição:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupo terapêutico:

Dogs

Área terapêutica:

canine parvovirus

Indicações terapêuticas:

Immunological - Live Vaccine

Status de autorização:

Authorised

Data de autorização:

2004-11-03

Características técnicas

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican P.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml dose of vaccine contains:
Freeze-dried pellet:
Attenuated canine parvovirus
>10
4.9
CCID
50
Excipients
q.s. 1 dose
For full list of excipients, see section 6.1.
CCID
50
= 50% cell culture infective dose.
3 PHARMACEUTICAL FORM
Lyophilisate for suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and puppies from 8 weeks of age.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of dogs from 8 weeks of age to prevent clinical
signs and to reduce mortality and viral excretion
caused by canine parvovirosis infection.
Onset of immunity:
7 days after primary vaccination
Duration of immunity:
2 years.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_5_
_/_
_0_
_5_
_/_
_2_
_0_
_1_
_2_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_2_
_3_
_5_
_4_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS:
The CPV vaccine strain of Eurican P may be shed from vaccinated
animals for a number of days following vaccination.
However, due to the absence of pathogenicity of the strain, it is not
necessary to keep vaccinated animals separated
from non-vaccinated animals.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS:
In the case of accidental self injection, seek medical